Calamos Advisors LLC Sells 30,670 Shares of Thermo Fisher Scientific Inc. $TMO

Calamos Advisors LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.1% during the first quarter, HoldingsChannel reports. The firm owned 139,230 shares of the medical research company’s stock after selling 30,670 shares during the quarter. Calamos Advisors LLC’s holdings in Thermo Fisher Scientific were worth $68,436,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. J. Stern & Co. LLP increased its holdings in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. Norges Bank bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $3,072,744,000. Auto Owners Insurance Co raised its holdings in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 2,183.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after purchasing an additional 1,270,643 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Thermo Fisher Scientific by 19.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock valued at $4,462,550,000 after acquiring an additional 1,230,872 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $528.62 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $403.36 and a one year high of $643.99. The firm has a market capitalization of $196.45 billion, a PE ratio of 29.06, a price-to-earnings-growth ratio of 2.33 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company has a 50-day simple moving average of $479.21 and a two-hundred day simple moving average of $515.66.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TMO shares. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Morgan Stanley reiterated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $602.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.